Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSITION20 trial of osimertinib in EGFR exon 20-mutant non-small cell lung cancer
NL-OMON26966Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Best response. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON26966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26966.